41 results about "Porcine influenza" patented technology

The invention relates to a vaccine strain of HIN1 swine influenza virus, wherein a classification naming is Swine influenza virus A / Swine / Nanjing / 50 / 2011 (H1N1), and a microbial accession number is CCTCCNO: V201218. According to the invention, isolation, identification and whole genome sequencing of the HIN1 swine influenza virus strain are carried out, and an inactivated vaccine against the swine flu is prepared by using the HIN1 swine influenza virus strain. The inactivated vaccine against the H1NI swine flu prepared from the virus strain can provide good protection for pigs attacked by homologous virulent strains, has good immunogenicity, and can effectively prevent H1NI swine flu with single vaccine or combined vaccines.

The invention discloses a method for determining titer of a swine flu inactivated vaccine. The method comprises the following steps: immunizing a pig with a swine flue inactivated vaccine, collecting blood 21-28 days after immunization and separating blood serum; removing non-specific components in the serum to obtain a serum to be tested; diluting the swine flue inactivated antigen, and preparing a unit swine flue antigen diluent with a concentration of 4HA; and diluting the serum to be tested by multiple proportions, successively adding the 4HA unit swine flue antigen diluent and 1% red cells to conduct hemagglutination inhibition test, so as to completely inhibit highest dilution of the 4HA unit swine flu antigen serum at HI titer. The method has advantages of greatly shortened measurement time, little operation error, strong controllability, and small inter-batch difference, and also reduces detection errors caused by different levels of experimental animals in an animal challenge protection experiment for testing the titer.

The invention belongs to the field of veterinary vaccines, particularly relates to a quad inactivated vaccine of PCV2-type baculovirus, swine mycoplasma hyopneumoniae, a porcine influenza virus and haemophilus parasuis and further discloses a preparation method for the quad inactivated vaccine and application of the quad inactivated vaccine. The quad inactivated vaccine disclosed by the inventioncontains inactivated protein Cap expressed by the PCV2-type baculovirus, inactivated swine mycoplasma hyopneumoniae, an inactivated porcine influenza virus H1N1subtype virus, inactivated haemophilus parasuis types 4, 5 and 13 and an adjuvant of the vaccine; four kinds of antigens are free of interference to one another, four kinds of protection can be achieved by one injection, and four kinds of epidemic diseases can be prevented through one-time immunization; and meanwhile, in view of toxic substance counteracting protection and serum antibody level, the immunization effect reaches or exceedsthat of each single commodity vaccine, the immunization duration is long, the efficacy is durable, and the quad inactivated vaccine has the advantages that the safety is good, the preparation methodis simple, the immunization is convenient, the immunization cost is reduced, and the like.

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.

The invention belongs to the field of biotechnology and relates to a novel separated strain swine influenza virus. The invention discloses two separated H9N2 swine influenza viruses. According to the invention, it firstly proves that the two strains both belong to Ck / Bei series. The invention also discloses a kit for detecting the H9N2 swine influenza viruses. Through the kit provided by the invention, whether swine flu is caused by the genotype of H9N2 swine influenza viruses can be rapidly detected or eliminated so as to control the swine flu epidemic situation as soon as possible. In addition, by the use of the kit, bioinformation for a swine influenza virus monitoring system can be provided.

The invention discloses a pathogenic bacteria killing and environment control breeding house applied to an epidemic prevention of swine influenza. The pathogenic bacteria killing and environment control breeding house comprises a breeding house body, shutter bodies and a device box, a house door is hinged and fixed to an outer side of the breeding house body, positioning columns are welded and fixed to a top part of the breeding house body, outer sides of the shutter bodies are connected with the breeding house body in an embedded mode, flexible solar panels are bonded and fixed to the outer side of the breeding house body, a waste collecting box is welded and fixed to a bottom plate of the breeding house, chassis supporting piles are welded and fixed to two sides of the waste collecting box, and pollution discharge pipelines are welded and fixed to a bottom plate of the waste collecting box. The pathogenic bacteria killing and environment control breeding house applied to an epidemicprevention of swine influenza is provided with first eccentric wheels and bevel gears, the first eccentric wheels are used for driving spraying supports to move left and right, a moving range betweenthe spraying supports is adjusted according to a width of the breeding house, and an interior of the breeding house can be conveniently and automatically sterilized.

A provided vaccine composition for preventing and treating porcine respiratory syndrome comprises immunization amount of porcine influenza virus antigen, immunization amount of porcine pneumonia mycoplasma antigen, immunization amount of haemophilus parasuis antigen, and an adjuvant. The vaccine composition is capable of effectively preventing and controlling porcine respiratory syndrome caused by mixed infection of the three kinds of pathogeny, and also is capable of reducing vaccine inoculating frequency and avoiding unavailable full-access immunization caused by missed inoculation.

The present invention relates to a vaccine composition for preventing and / or treating porcine circovirus disease and swine influenza and its preparation method and application. Circular virus subunit antigen and nucleic acid capable of being expressed in pigs, and ii) swine influenza virus subunit antigen or nucleic acid encoding swine influenza virus subunit antigen and capable of being expressed in pigs. The present invention also relates to nucleic acid molecules, recombinant plasmids and host cells for simultaneous treatment and / or prevention of two porcine diseases.

This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof.

The invention belongs to the technical fields of zoonosis and animal transgenes, and particularly relates application of a PBD (porcine beta-defensins 2) gene in resisting of swine influenza. The application has the advantages that the segments of the PBD-2 gene are excessively expressed in a swine body, so as to obviously improve the resistance ability of the transgenic swine on the swine influenza, namely that the excessively expressed PBD-2 can obviously reduce the virus titer of swine influenza virus in lung tissues of the infected swine and the lesion degree of swine lung due to infectionby the swine influenza virus; by synthesizing or recombining the PBD-2 gene, the duplication of the swine influenza virus can be effectively inhibited; the polypeptide medicines or feed additives canbe prepared by in-vitro expression or synthesizing of the PBD-2 gene.

Provided feed for controlling pig influenza comprises the raw materials: corn, soybean meal, edible salt, fish meal, soybean oil, zinc methionine, copper lysine, tryptophan, vitamin A, vitamin E, ethoxyquin and a traditional Chinese medicine composition feed additive for controlling pig influenza. The traditional Chinese medicine composition feed additive is abundant in drug source, relatively low in residual toxicity or free of residual toxicity, small in side effect and not easy for generating of drug resistance, is capable of regulating body immune function, inhibiting virus replication and improving disease symptoms, and has substantial effect on controlling pig influenza.

The invention provides a mixed virus-like particles, containing stromatin M1 of influenza virus, surface antigen erythrohemagglutinin HA of influenza virus and a nexus protein containing main antigenic epitope contained capsid protein of foot and mouth disease virus and a transmembrane zone and an inner membrane zone of the erythrohemagglutinin HA of influenza virus. The main antigenic epitope contained capsid protein of foot and mouth disease virus substitutes a basically same length outer membrane zone of a 5' terminal of the erythrohemagglutinin HA of influenza virus. Surface antigen erythrohemagglutinin HA of influenza virus and the main antigenic epitope contained capsid protein of foot and mouth disease virus are expressed simultaneously on surfaces of the mixed virus-like particles. The invention also provides a divalent vaccine of swine influenza and foot and mouth disease; and the vaccine contains the mixed virus-like particles and adjuvants. The invention also provides a method for preparing the mixed virus-like particles.

The invention discloses a method for determining titer of a swine flu inactivated vaccine. The method comprises the following steps: immunizing a pig with a swine flue inactivated vaccine, collecting blood 21-28 days after immunization and separating blood serum; removing non-specific components in the serum to obtain a serum to be tested; diluting the swine flue inactivated antigen, and preparing a unit swine flue antigen diluent with a concentration of 4HA; and diluting the serum to be tested by multiple proportions, successively adding the 4HA unit swine flue antigen diluent and 1% red cells to conduct hemagglutination inhibition test, so as to completely inhibit highest dilution of the 4HA unit swine flu antigen serum at HI titer. The method has advantages of greatly shortened measurement time, little operation error, strong controllability, and small inter-batch difference, and also reduces detection errors caused by different levels of experimental animals in an animal challenge protection experiment for testing the titer.

The invention belongs to the field of microbial virology and provides a swine influenza A H1N1 virus. The virus contains eight fragments, namely HA, NA, NP, PB1, PB2, PA, NS and M, wherein the nucleotide sequences of the eight fragments are shown by the sequences from No.1 to No.8 in a nucleotide sequence table in the description in turn. In the invention, by separate culture of a nasopharyngeal swab sample of a healthy pig, differential item functioning (DIF) and reverse transcription-polymerase chain reaction (RT-PCR) identification and the comparison of full sequences of 8 genes of the virus, a virus is obtained and verified to be a swine influenza A H1N1 virus strain. The swine influenza A H1N1 virus strain is named A / swine / Zhejiang / 26 / 2009(H1N1), with a collection number of CCTCC No.V201016. The strain obtained by the invention supplies valuable genetic information of swine influenza A virus in China, has a great significance for completing a system for monitoring the infection caused by the pathogen and can be used for preparing a reagent for quickly diagnosing infection with the influenza A H1N1 virus.